Monte Rosa Therapeutics (NASDAQ:GLUE) Issues Earnings Results

Monte Rosa Therapeutics (NASDAQ:GLUE) posted its quarterly earnings data on Thursday. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05), FiscalAI reports. The company had revenue of $8.97 million during the quarter, compared to analyst estimates of $12.91 million. Monte Rosa Therapeutics had a negative net margin of 560.85% and a negative return on equity of 48.30%.

Monte Rosa Therapeutics Trading Up 1.1%

Shares of GLUE stock traded up $0.17 during midday trading on Friday, reaching $15.88. 1,031,388 shares of the stock were exchanged, compared to its average volume of 1,631,805. The firm has a market cap of $1.34 billion, a PE ratio of -9.02 and a beta of 1.59. The company’s 50 day moving average is $20.53 and its two-hundred day moving average is $19.35. Monte Rosa Therapeutics has a 1 year low of $4.12 and a 1 year high of $25.77.

Insider Buying and Selling at Monte Rosa Therapeutics

In related news, COO Jennifer Champoux sold 2,175 shares of Monte Rosa Therapeutics stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $20.00, for a total transaction of $43,500.00. Following the completion of the transaction, the chief operating officer directly owned 62,371 shares of the company’s stock, valued at $1,247,420. This trade represents a 3.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Sharon Townson sold 6,000 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $23.31, for a total value of $139,860.00. Following the completion of the transaction, the insider directly owned 67,845 shares in the company, valued at $1,581,466.95. This trade represents a 8.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 81,778 shares of company stock worth $1,768,581. Corporate insiders own 6.40% of the company’s stock.

Institutional Trading of Monte Rosa Therapeutics

Institutional investors have recently made changes to their positions in the business. MetLife Investment Management LLC grew its stake in Monte Rosa Therapeutics by 7.5% during the fourth quarter. MetLife Investment Management LLC now owns 26,187 shares of the company’s stock valued at $411,000 after acquiring an additional 1,831 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Monte Rosa Therapeutics by 2.2% during the second quarter. The Manufacturers Life Insurance Company now owns 119,836 shares of the company’s stock valued at $540,000 after purchasing an additional 2,529 shares in the last quarter. Lazard Asset Management LLC increased its holdings in shares of Monte Rosa Therapeutics by 42.9% in the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after purchasing an additional 3,262 shares during the last quarter. Man Group plc lifted its position in shares of Monte Rosa Therapeutics by 11.5% in the third quarter. Man Group plc now owns 40,575 shares of the company’s stock worth $301,000 after buying an additional 4,184 shares in the last quarter. Finally, Russell Investments Group Ltd. bought a new position in Monte Rosa Therapeutics during the third quarter valued at approximately $32,000. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Zacks Research raised shares of Monte Rosa Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday. JPMorgan Chase & Co. cut their price target on shares of Monte Rosa Therapeutics from $31.00 to $27.00 and set an “overweight” rating on the stock in a report on Friday. Wells Fargo & Company dropped their price objective on Monte Rosa Therapeutics from $29.00 to $27.00 and set an “overweight” rating on the stock in a research note on Friday. Guggenheim cut their target price on shares of Monte Rosa Therapeutics from $35.00 to $28.00 and set a “buy” rating for the company in a research report on Friday. Finally, Wedbush cut their price target on Monte Rosa Therapeutics from $37.00 to $27.00 and set an “outperform” rating for the company in a report on Monday, August 3rd. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.50.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.